TQB-3456

N/A

Report date: 2023/12/25 20:04:51
NME

Base Information

Drug NameTQB-3456
Drug Alias NameTQB-3456
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdLianyungang Runzhong Pharmaceutical Co LtdBeijing Centaurus Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdBeijing Centaurus Biopharma Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A